Join us to explore how our API expertise can help you drive success
April 17Th - 19Th, 2024
East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, JapanOur Team at CPHI Japan 2024
-
Nirav Shah
Vice President and Region Head
-
Masahiro Wakabayashi
Regional Sales Manager, Sales and Marketing
-
Takayuki Hato
Region Head - Japan, Sales and Marketing
-
Natasha Kumari
Customer Service Manager, API Marketing & Sales - North Asia
-
Dr. Rajeev Rehani Budhdev
Executive Vice President – API R&D
About CPHI Japan 2024
CPHI Japan 2024 is a leading annual trade event focusing on the pharmaceutical industry in Japan. Held at the Tokyo Big Sight (East Halls 4, 5 & 6) from April 17th to 19th, 2024, the event brings together a comprehensive range of exhibitors and attendees from across the pharmaceutical supply chain.
Attendees can expect to:
- Explore the latest advancements and solutions showcased by exhibitors covering pharma ingredients, outsourcing services, biopharmaceuticals, pharmaceutical machinery & equipment, and drug delivery systems & packaging.
- Network with industry professionals from Japan and around the world, fostering potential business partnerships.
- Gain valuable knowledge through conferences and presentations delivered by industry experts, staying abreast of current trends and insights within the Japanese pharmaceutical market.
CPHI Japan 2024 serves as a platform for industry stakeholders to connect, exchange information, and explore business opportunities within the Japanese pharmaceutical landscape.
About Dr.Reddy's API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 180+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Our Achievements
2023
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
2023
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
2022
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
2020
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
2020
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
2019
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our Plants
Renuncia
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.